Funabashi Nobusada, Takaoka Hiroyuki, Ozawa Koya, Uehara Masae, Komuro Issei, Kobayashi Yoshio
Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8670, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Heart Vessels. 2018 Sep;33(9):1046-1051. doi: 10.1007/s00380-018-1155-z. Epub 2018 Mar 22.
We used peak longitudinal strain (PLS) on TTE in HCM patients to differentiate LV myocardium (LVM) into the following 4 groups: group 1-no fibrosis or hypertrophy (≥ 13 mm), group 2-no fibrosis but hypertrophy evident, group 3-fibrosis present but without hypertrophy, and group 4-both fibrosis and hypertrophy. Seventeen HCM patients (13 males, 56 ± 16 years) underwent both 1.5 T CMR and TTE. On TTE, PLS (absolute values) for each LVM segment from 17 AHA-defined lesions was calculated. Of 289 LVM lesions, the numbers in each group, 1-4, were 156, 53, 39, and 41, respectively. PLS for LVM segments in group 1 (13.6 ± 6.4%) were significantly greater than those in group 2 (8.5 ± 4.9%, P < 0.001), group 3 (10.4 ± 5.0%, P = 0.006), and group 4 (7.1 ± 4.4%, P < 0.001). PLS for LVM segments in group 3 was significantly greater than those in group 4 (P = 0.016). However, significant differences in PLS in LVM between groups 2 and 3, and between 2 and 4 were not observed. Using regional PLS, we demonstrate successful differentiation of LVM in HCM patients for group 1 (LVM with zero fibrosis or hypertrophy) from LVM belonging to groups 2-4 and we also demonstrate successful differentiation of LVM with fibrosis present but without hypertrophy from LVM with both fibrosis and hypertrophy. However, it is not possible to differentiate between LVM with no fibrosis but hypertrophy evident and those with fibrosis present but without hypertrophy and also between LVM with no fibrosis but hypertrophy evident and those with both fibrosis and hypertrophy. Our findings have significant implications for the management of HCM patients.
我们利用肥厚型心肌病(HCM)患者经胸超声心动图(TTE)检查中的纵向应变峰值(PLS),将左心室心肌(LVM)分为以下4组:第1组——无纤维化或肥厚(≥13毫米);第2组——无纤维化但有明显肥厚;第3组——有纤维化但无肥厚;第4组——既有纤维化又有肥厚。17例HCM患者(13例男性,年龄56±16岁)接受了1.5T心脏磁共振成像(CMR)和TTE检查。在TTE检查中,计算了17个美国心脏协会(AHA)定义节段中每个LVM节段的PLS(绝对值)。在289个LVM病变中,第1 - 4组的病变数量分别为156、53、39和41个。第1组LVM节段的PLS(13.6±6.4%)显著高于第2组(8.5±4.9%,P<0.001)、第3组(10.4±5.0%,P = 0.006)和第4组(7.1±4.4%,P<0.001)。第3组LVM节段的PLS显著高于第4组(P = 0.016)。然而,未观察到第2组和第3组之间以及第2组和第4组之间LVM的PLS存在显著差异。利用节段性PLS,我们成功区分了HCM患者中第1组(无纤维化或肥厚的LVM)与第2 - 4组的LVM,并且成功区分了有纤维化但无肥厚的LVM与既有纤维化又有肥厚的LVM。然而,无法区分无纤维化但有明显肥厚的LVM与有纤维化但无肥厚的LVM,也无法区分无纤维化但有明显肥厚的LVM与既有纤维化又有肥厚的LVM。我们的研究结果对HCM患者的管理具有重要意义。